Song Dayoung, Pallas Sarah W, Shimpi Rahul, Ramaswamy N, Haldar Pradeep, Harvey Pauline, Bhatnagar Pankaj, Katkar Arun, Jayaprasad Niniya, Kunwar Abhishek, Bahl Sunil, Morgan Win, Hutubessy Raymond, Date Kashmira, Mogasale Vittal
Policy and Economic Research Department, International Vaccine Institute, Seoul, Republic of Korea.
Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
PLOS Glob Public Health. 2023 Jan 4;3(1):e0001396. doi: 10.1371/journal.pgph.0001396. eCollection 2023.
Navi Mumbai Municipal Corporation (NMMC), a local government in Mumbai, India, implemented the first public sector TCV campaign in 2018. This study estimated the delivery costs of this TCV campaign using a Microsoft Excel-based tool based on a micro-costing approach from the government (NMMC) perspective. The campaign's financial (direct expenditures) and economic costs (financial costs plus the monetized value of additional donated or existing items) incremental to the existing immunization program were collected. The data collection methods involved consultations with NMMC staff, reviews of financial and programmatic records of NMMC and the World Health Organization (WHO), and interviews with the health staff of sampled urban health posts (UHPs). Three UHPs were purposively sampled, representing the three dominant residence types in the catchment area: high-rise, slum, and mixed (high-rise and slum) areas. The high-rise area UHP had lower vaccination coverage (47%) compared with the mixed area (71%) and slum area UHPs (76%). The financial cost of vaccine and vaccination supplies (syringes, safety boxes) was $1.87 per dose, and the economic cost was $2.96 per dose in 2018 US dollars. Excluding the vaccine and vaccination supplies cost, the financial delivery cost across the 3 UHPs ranged from $0.37 to $0.53 per dose, and the economic delivery cost ranged from $1.37 to $3.98 per dose, with the highest delivery costs per dose in the high-rise areas. Across all 11 UHPs included in the campaign, the weighted average financial delivery cost was $0.38 per dose, and the economic delivery cost was $1.49 per dose. WHO has recommended the programmatic use of TCV in typhoid-endemic countries, and Gavi has included TCV in its vaccine portfolio. This first costing study of large-scale TCV introduction within a public sector immunization program provides empirical evidence for policymakers, stakeholders, and future vaccine campaign planning.
印度孟买的地方政府新孟买市政公司(NMMC)于2018年开展了首个公共部门伤寒结合疫苗(TCV)接种运动。本研究从政府(NMMC)的角度,使用基于微观成本核算方法的微软Excel工具,估算了此次TCV接种运动的实施成本。收集了该接种运动相对于现有免疫规划增加的财务成本(直接支出)和经济成本(财务成本加上额外捐赠或现有物品的货币化价值)。数据收集方法包括与NMMC工作人员协商、审查NMMC和世界卫生组织(WHO)的财务和项目记录,以及采访抽样城市卫生站(UHP)的卫生工作人员。有目的地选取了三个UHP,分别代表集水区内三种主要的居住类型:高层、贫民窟和混合(高层和贫民窟)地区。与混合地区(71%)和贫民窟地区的UHP(76%)相比,高层地区的UHP疫苗接种覆盖率较低(47%)。2018年美元价值下,疫苗和接种用品(注射器、安全盒)的财务成本为每剂1.87美元,经济成本为每剂2.96美元。不包括疫苗和接种用品成本,三个UHP的财务实施成本为每剂0.37美元至0.53美元,经济实施成本为每剂1.37美元至3.98美元,高层地区每剂的实施成本最高。在该接种运动涵盖的所有11个UHP中,加权平均财务实施成本为每剂0.38美元,经济实施成本为每剂1.49美元。世卫组织已建议在伤寒流行国家将TCV用于项目实施,全球疫苗免疫联盟(Gavi)也已将TCV纳入其疫苗组合。这项在公共部门免疫规划中首次大规模引入TCV的成本核算研究,为政策制定者、利益相关者及未来的疫苗接种运动规划提供了实证依据。